First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts

Morten Persson; Hongguang Liu; Jacob Madsen; Zhen Cheng; Andreas Kjaer

doi:10.1016/j.nucmedbio.2013.03.001

First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts

Morten Persson, Hongguang Liu, Jacob Madsen, Zhen Cheng, Andreas Kjaer

Afdeling for Klinisk Fysiologi og Nuklearmedicin

40 Citationer (Scopus)

Abstract

Urokinase-type plasminogen activator receptor (uPAR) is overexpressed in human prostate cancer and uPAR has been found to be associated with metastatic disease and poor prognosis. AE105 is a small linear peptide with high binding affinity to uPAR. We synthesized an N-terminal NOTA-conjugated version (NOTA-AE105) for development of the first (18)F-labeled uPAR positron-emission-tomography PET ligand using the Al(18)F radiolabeling method. In this study, the potential of (18)F-AlF-NOTA-AE105 to specifically target uPAR-positive prostate tumors was investigated.

Originalsprog	Engelsk
Tidsskrift	Nuclear Medicine and Biology
Vol/bind	40
Udgave nummer	5
Sider (fra-til)	618-24
Antal sider	7
ISSN	0969-8051
DOI	https://doi.org/10.1016/j.nucmedbio.2013.03.001
Status	Udgivet - jul. 2013

Adgang til dokumentet

10.1016/j.nucmedbio.2013.03.001

Citationsformater

@article{3589de5c575744adb1d9514f0820cc58,

title = "First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts",

abstract = "Urokinase-type plasminogen activator receptor (uPAR) is overexpressed in human prostate cancer and uPAR has been found to be associated with metastatic disease and poor prognosis. AE105 is a small linear peptide with high binding affinity to uPAR. We synthesized an N-terminal NOTA-conjugated version (NOTA-AE105) for development of the first (18)F-labeled uPAR positron-emission-tomography PET ligand using the Al(18)F radiolabeling method. In this study, the potential of (18)F-AlF-NOTA-AE105 to specifically target uPAR-positive prostate tumors was investigated.",

keywords = "Animals, Cell Line, Tumor, Cell Transformation, Neoplastic, Fluorine Radioisotopes, Gene Expression Regulation, Neoplastic, Heterocyclic Compounds, Humans, Isotope Labeling, Ligands, Male, Mice, Oligopeptides, Positron-Emission Tomography, Prostatic Neoplasms, Radiochemistry, Receptors, Urokinase Plasminogen Activator",

author = "Morten Persson and Hongguang Liu and Jacob Madsen and Zhen Cheng and Andreas Kjaer",

year = "2013",

month = jul,

doi = "10.1016/j.nucmedbio.2013.03.001",

language = "English",

volume = "40",

pages = "618--24",

journal = "Nuclear Medicine and Biology",

issn = "0969-8051",

publisher = "Elsevier Inc",

number = "5",

}

TY - JOUR

T1 - First (18)F-labeled ligand for PET imaging of uPAR

T2 - in vivo studies in human prostate cancer xenografts

AU - Persson, Morten

AU - Liu, Hongguang

AU - Madsen, Jacob

AU - Cheng, Zhen

AU - Kjaer, Andreas

PY - 2013/7

Y1 - 2013/7

N2 - Urokinase-type plasminogen activator receptor (uPAR) is overexpressed in human prostate cancer and uPAR has been found to be associated with metastatic disease and poor prognosis. AE105 is a small linear peptide with high binding affinity to uPAR. We synthesized an N-terminal NOTA-conjugated version (NOTA-AE105) for development of the first (18)F-labeled uPAR positron-emission-tomography PET ligand using the Al(18)F radiolabeling method. In this study, the potential of (18)F-AlF-NOTA-AE105 to specifically target uPAR-positive prostate tumors was investigated.

AB - Urokinase-type plasminogen activator receptor (uPAR) is overexpressed in human prostate cancer and uPAR has been found to be associated with metastatic disease and poor prognosis. AE105 is a small linear peptide with high binding affinity to uPAR. We synthesized an N-terminal NOTA-conjugated version (NOTA-AE105) for development of the first (18)F-labeled uPAR positron-emission-tomography PET ligand using the Al(18)F radiolabeling method. In this study, the potential of (18)F-AlF-NOTA-AE105 to specifically target uPAR-positive prostate tumors was investigated.

KW - Animals

KW - Cell Line, Tumor

KW - Cell Transformation, Neoplastic

KW - Fluorine Radioisotopes

KW - Gene Expression Regulation, Neoplastic

KW - Heterocyclic Compounds

KW - Humans

KW - Isotope Labeling

KW - Ligands

KW - Male

KW - Mice

KW - Oligopeptides

KW - Positron-Emission Tomography

KW - Prostatic Neoplasms

KW - Radiochemistry

KW - Receptors, Urokinase Plasminogen Activator

U2 - 10.1016/j.nucmedbio.2013.03.001

DO - 10.1016/j.nucmedbio.2013.03.001

M3 - Journal article

C2 - 23602763

SN - 0969-8051

VL - 40

SP - 618

EP - 624

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

IS - 5

ER -

First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater